List of Patanase drug patents
Patanase is owned by Novartis.
Patanase contains Olopatadine Hydrochloride.
Patanase has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Patanase are:
- US8399508
- US7977376
- US8399508*PED
Patanase was authorised for market use on 15 April, 2008.
Patanase is available in spray, metered;nasal dosage forms.
Patanase can be used as allergic rhinitis.
The generics of Patanase are possible to be released after 02 August, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399508 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Sep, 2022
(6 months ago) | |
| US7977376 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Feb, 2023
(a month ago) | |
|
US8399508
(Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Mar, 2023
(3 days ago) | |
|
US7977376
(Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Aug, 2023
(4 months from now) | |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2008
Treatment: Allergic rhinitis
Dosage: SPRAY, METERED;NASAL
PATANASE family patents
6
United States
5
Japan
1
Portugal
1
Germany
1
Spain
1
Brazil
1
Argentina
1
Mexico
1
Austria
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
South Africa
1
Canada
1
Poland
1
GC
1
Australia
1
Denmark
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic